It was proved that the CMTM6 expression within PAAD was greatly higher through the above analysis, which prompted us to further investigate the impact of the elevated CMTM6 expression on the clinical features as well as survival time for PAAD patients. This evidence concerns the gene CMTM6 and pancreatic adenocarcinoma.